Cargando…

Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists

BACKGROUND: Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at an increased risk of recurrent thromboembolic events (TEs) and hemorrhagic complications. Anticoagulation with vitamin K antagonists...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fedorov, Kateryna, Goel, Swati, Kushnir, Margarita, Billett, Henny H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440942/ https://www.ncbi.nlm.nih.gov/pubmed/34532628 http://dx.doi.org/10.1002/rth2.12574

Ejemplares similares

Identifying Neutrophil Extracellular Traps (NETs) in Blood Samples Using Peripheral Smear Autoanalyzers
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
por: Barbui, Tiziano, et al.
Publicado: (2021)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
por: How, Joan, et al.
Publicado: (2021)

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms
por: Dambrauskienė, Rūta, et al.
Publicado: (2023)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
por: Ferrer-Marín, Francisca, et al.
Publicado: (2021)

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
por: Paciaroni, Maurizio, et al.
Publicado: (2021)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Saddle Pulmonary Embolism: Demographics, Clinical Presentation, and Outcomes
por: Wong, Kevin J., et al.
Publicado: (2021)

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus
por: Iqbal, Hansa, et al.
Publicado: (2020)

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study
por: Baker, Ross I., et al.
Publicado: (2023)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic
por: Langabeer, Stephen E.
Publicado: (2020)

Increased incidence of thrombosis in a cohort of cancer patients with COVID-19
por: Zavras, Phaedon D., et al.
Publicado: (2021)

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
por: Liu, Angela, et al.
Publicado: (2022)

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
por: Borsani, Oscar, et al.
Publicado: (2022)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older
por: Manckoundia, Patrick, et al.
Publicado: (2021)

Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry
por: Pfeilschifter, Waltraud, et al.
Publicado: (2022)

Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus
por: Huang, Lei, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Angiogenesis in myeloproliferative neoplasms, new markers and future directions
por: Medinger, Michael, et al.
Publicado: (2014)

Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
por: Yamkasikorn, Janekij, et al.
Publicado: (2022)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5b003nspqmlvcbahl98okv6dgn